New Two-Drug attack on Tough-to-Treat cancers begins human testing
NCT ID NCT06166836
Summary
This study is testing a new combination of two drugs, D-1553 and IN10018, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe dose for the combination and to see if it can shrink tumors in patients with cancers like colorectal cancer, lung cancer, and others. This is an early-phase trial for adults who have already tried standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Bengbu Medical College
Bengbu, China
-
First Affiliated Hospital of Gannan Medical University
Ganzhou, China
-
Fujian Cancer Hospital
Fuzhou, China
-
General Hospital Of Eastern Theater Command
Nanjing, China
-
Henan Cancer Hospital
Zhengzhou, China
-
Hunan Cancer Hospital
Changsha, China
-
Renmin Hospital of Wuhan University
Wuhan, China
-
The first Affiliated Hospital of Zhengzhou University
Zhengzhou, China
-
Xuzhou Central Hospital
Xuzhou, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310005, China
Conditions
Explore the condition pages connected to this study.